HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localization
HIV-1 gp120诱导的CTL化学排斥:迁移失调
基本信息
- 批准号:7662414
- 负责人:
- 金额:$ 41.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-04-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemActive SitesAcuteAnimalsAntigensAscaridilBindingBiological AssayBiomedical EngineeringBone MarrowCCR5 geneCD4 Positive T LymphocytesCXCR4 geneCancer ModelCellsChemotactic FactorsChemotaxisCollaborationsCytolysisCytotoxic T-LymphocytesDataDevelopmentDisease ProgressionDown-RegulationDyesElementsEmigrationsFunctional disorderGenerationsHIVHIV 1 Envelope Protein gp120HIV Envelope Protein gp120HIV-1Helper-Inducer T-LymphocyteHighly Active Antiretroviral TherapyHistocompatibility Antigens Class IHumanImageImmuneImmune systemImmunologistImmunotherapeutic agentImmunotherapyIn VitroIncidenceIndividualInfectionLabelLaboratoriesLeukocytesLigandsLymphocyte FunctionLymphoid TissueMagnetic Resonance ImagingMalignant NeoplasmsMature T-LymphocyteMeasuresMediatingMedicineModelingMonkeysMovementMusMutationNaturePathologic ProcessesPhysiologicalPlayPrevalenceProcessProteinsPublishingResearch Project GrantsRestRoleSignal PathwaySignal TransductionSiteStromal Cell-Derived Factor 1SurfaceT-LymphocyteT-Lymphocyte EpitopesTechnologyTherapeutic InterventionThymus GlandTissuesUnited States National Institutes of HealthUpper armV3 LoopVaccine DesignViralViral ProteinsViruscell motilitycell typecellular engineeringchemokinechemokine receptordesignenv Gene Productshuman datain vivoinnovationintravital microscopylymph nodesmigrationmonocyteneoplastic cellnovelpreventresponsevaccine candidate
项目摘要
DESCRIPTION (provided by applicant): Immune control of HIV-1 is dependent on the migration of HIV-1 specific CTLs towards and colocalization with infected cells. This process is orchestrated by the action of chemokines serving as chemoattractants at sites of infection. We recently demonstrated that leukocytes could also be repelled from specific agents including chemokines and viral proteins including SDF-1 and the HIV-1 envelope protein, gp120 via a chemokine receptor mediated mechanism termed fugetaxis or chemorepulsion (Nature Medicine.2000.6.543; J Virol. 2004: 2004: 78.5184; Reviewed in J.Mol.Med..2005.83:752). We propose that T cell and in particular CTL chemorepulsion in response to CXCR4 or CCR5 binding gp120 generated from retrovirally infected cells plays a role in a novel mechanism by which HIV-1 evades the immune system. First we developed novel fully quantitative assays for measuring leukocyte migration to SDF-1 or HIV-1gp120 and demonstrated that chemorepulsion was mediated via a signaling pathway which was distinct from that for chemoattraction (Nature Med., J. Virol op cit; J. Leuk. Biol. 2005. in press.). In order to determine whether T cell chemorepulsion to SDF-1 or HIV-1gp120 was demonstrable in vivo, we established novel assays for quantitating leukocyte chemorepulsion and subsequently demonstrated its role in physiological and pathological processes including thymic emigration and immune evasion by cancer (J. Clin. Invest. 2002.109:1101; J. Immunol. 2005.175:5115)( J. Immunol. Accepted Dec.2005). We also showed that antigen specific CTLs and monocytes move away from X4 or R5 binding HIV-1 gp120 in vitro and in vivo and that this response was critically dependent on the presence of the V3 loop of the envelope protein (./ Virol. op cit.}. We have demonstrated in pilot that cells engineered to express gp120 repel and thereby dysregulate CTL migration and function in vitro and their subsequent localization in vivo and that chemorepellent concentrations of gp120 are detectable within the lymph nodes of acutely SHIV-1 infected monkeys. We now plan to explore the mechanism and pathophysiological relevance of these findings to HIV/AIDS. The aims of this proposal are 1: Definition of mechanistic elements of HIV-1gp120 induced CTL chemorepulsion and the effect of chemorepellent concentrations of the retroviral protein on CTL function. 2. Quantitation of the effects of X4gp120 on CTL migration, localization and function in murine models using multiphoton intravital microscopy and MRI for imaging dye or nanomagnetically labeled CTLs in vivo. 3. Quantitation and modeling of gp120 gradients in tissues and correlation with the localization and function of CTLs in acutely SHIV-1 infected monkeys. This focused and innovative exploration of the pathophysiological relevance of HIV-1 gp120 induced CTL chemorepulsion to HIV/AIDS is supported by synergistic and ongoing collaborations between retrovirologists, immunologists and bioengineers and access to recently developed fully quantitative technologies for examining T cell migration and localization in vitro and in vivo. We hope, in this way, to delineate both a novel mechanism by which HIV-1 evades the immune system and a new immunotherapeutic target for HIV-1 infected individuals.
描述(由申请方提供):HIV-1的免疫控制依赖于HIV-1特异性CTL向感染细胞的迁移和与感染细胞的共定位。这个过程是由在感染部位充当化学引诱物的趋化因子的作用协调的。我们最近证明,白细胞也可以通过称为趋化性或化学排斥的趋化因子受体介导的机制被排斥于包括趋化因子和病毒蛋白(包括SDF-1和HIV-1包膜蛋白,gp 120)的特定试剂(Nature Medicine.2000.6.543; J Virol. 2004:2004:78.5184;在J.Mol. Med.中综述。2005.83:752)。我们建议,T细胞,特别是CTL的化学排斥反应CXCR 4或CCR 5结合gp 120产生的逆转录病毒感染的细胞中发挥作用的一种新的机制,HIV-1逃避免疫系统。首先,我们开发了用于测量白细胞向SDF-1或HIV-1gp 120迁移的新的完全定量测定,并证明了化学排斥是通过与化学吸引不同的信号传导途径介导的(Nature Med.,J. Virol op cit; J.勒克. Biol.2005. in press.)。为了确定T细胞对SDF-1或HIV-1gp 120的化学排斥是否在体内可证实,我们建立了用于定量白细胞化学排斥的新测定,并随后证实了其在生理和病理过程中的作用,包括胸腺移出和癌症的免疫逃避(J.Clin.Invest.2004)。2002.109:1101; J.Immunol.2005.175:5115)(J.Immunol.AcceptedDec.2005)。我们还表明,抗原特异性CTL和单核细胞在体外和体内远离结合HIV-1 gp 120的X4或R5,并且这种反应严重依赖于包膜蛋白的V3环的存在(. Virol.同上。我们已经证明,在试点工程细胞表达gp 120排斥,从而失调的CTL迁移和功能在体外和随后的定位在体内,并在急性SHIV-1感染的猴子的淋巴结内检测到的gp 120的化学排斥浓度。我们现在计划探索这些发现与HIV/AIDS的机制和病理生理学相关性。本研究的目的是:1. HIV-1gp 120诱导CTL化学排斥的机制和逆转录病毒蛋白的化学排斥浓度对CTL功能的影响。2.使用多光子活体显微镜和MRI对染料或纳米磁性标记的CTL进行体内成像,定量X4 gp 120对小鼠模型中CTL迁移、定位和功能的影响。3.组织中gp 120梯度的定量和建模以及与急性SHIV-1感染猴中CTL的定位和功能的相关性HIV-1 gp 120诱导的CTL化学排斥对HIV/AIDS的病理生理学相关性的这种集中和创新的探索得到了逆转录病毒学家,免疫学家和生物工程师之间的协同和持续合作的支持,并获得了最近开发的用于检查T细胞迁移和体外和体内定位的完全定量技术。我们希望,通过这种方式,描绘出一种新的机制,通过这种机制,HIV-1逃避免疫系统和HIV-1感染者的新的免疫靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK Coleman POZNANSKY其他文献
MARK Coleman POZNANSKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK Coleman POZNANSKY', 18)}}的其他基金
HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localization
HIV-1 gp120诱导的CTL化学排斥:迁移失调
- 批准号:
8141673 - 财政年份:2010
- 资助金额:
$ 41.05万 - 项目类别:
HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localization
HIV-1 gp120诱导的CTL化学排斥:迁移失调
- 批准号:
7900116 - 财政年份:2009
- 资助金额:
$ 41.05万 - 项目类别:
Movement of Recipient T-Cells Away From an Allograft
受体 T 细胞远离同种异体移植物的运动
- 批准号:
6352372 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
Active Movement of Immune Cells Away From HIV-1 gp120
免疫细胞主动运动远离 HIV-1 gp120
- 批准号:
6511570 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
Active Movement of Immune Cells Away From HIV-1 gp120
免疫细胞主动运动远离 HIV-1 gp120
- 批准号:
6717680 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
Active Movement of Immune Cells Away From HIV-1 gp120
免疫细胞主动运动远离 HIV-1 gp120
- 批准号:
6632464 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
Movement of Recipient T-Cells Away From an Allograft
受体 T 细胞远离同种异体移植物的运动
- 批准号:
6534341 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
Active Movement of Immune Cells Away From HIV-1 gp120
免疫细胞主动运动远离 HIV-1 gp120
- 批准号:
6348392 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
Active Movement of Immune Cells Away From HIV-1 gp120
免疫细胞主动运动远离 HIV-1 gp120
- 批准号:
6867443 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localization
HIV-1 gp120诱导的CTL化学排斥:迁移失调
- 批准号:
7465463 - 财政年份:2001
- 资助金额:
$ 41.05万 - 项目类别:
相似海外基金
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334970 - 财政年份:2024
- 资助金额:
$ 41.05万 - 项目类别:
Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
- 批准号:
2400195 - 财政年份:2024
- 资助金额:
$ 41.05万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334969 - 财政年份:2024
- 资助金额:
$ 41.05万 - 项目类别:
Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
- 批准号:
23K04919 - 财政年份:2023
- 资助金额:
$ 41.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
- 批准号:
22KJ2957 - 财政年份:2023
- 资助金额:
$ 41.05万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
- 批准号:
23K04494 - 财政年份:2023
- 资助金额:
$ 41.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
- 批准号:
23K13831 - 财政年份:2023
- 资助金额:
$ 41.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
- 批准号:
2238379 - 财政年份:2023
- 资助金额:
$ 41.05万 - 项目类别:
Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
- 批准号:
2154399 - 财政年份:2022
- 资助金额:
$ 41.05万 - 项目类别:
Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
- 批准号:
RGPIN-2019-06633 - 财政年份:2022
- 资助金额:
$ 41.05万 - 项目类别:
Discovery Grants Program - Individual